Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as well as in both metastatic and early stage breast cancer. FLORENCE, Italy and NEW YORK,...
HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025
Early Phase 1 monotherapy data demonstrate cytopenia-sparing safety, broad pharmacologic window, and early clinical activity in relapsed/refractory non-Hodgkin lymphoma (NHL) TAIPEI, SHANGHAI, and SAN FRANCISCO, Dec. 8, 2025 /PRNewswire/ --...
IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
SHANGHAI and NANJING, China and PLEASANTON, Calif., Dec. 8, 2025 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell...
Clarivate Presents Cortellis Regulatory AI Assistant to Cut Through Complexity in Safety and Compliance
Powered by agentic AI, new features help regulatory teams improve accuracy and enable faster, more confident decisions across the product lifecycle LONDON, Dec. 4, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of...
Nature Communications | Insilico Medicine Presents AI-empowered Dual-Action PROTAC Targeting PKMYT1
AI Designs a Novel RPOTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its complex linker, demonstrating a powerful, end-to-end...
The St. Regis Macao Presents the House of Celebration this Festive Season
Timeless rituals and curated indulgences inspire a season of sophisticated wonder MACAO, Nov. 25, 2025 /PRNewswire/ -- The St. Regis Macao is delighted to unveil its enchanting programme of festive celebrations, transforming the hotel into the...
Phrozen Presents ARCO: Fast, Full-Color FDM 3D Printing for Creative Minds
TAIPEI, Nov. 10, 2025 /PRNewswire/ -- Phrozen, renowned for its leadership in resin 3D printing, expands its ecosystem with a refreshed look at ARCO, the company's first FDM 3D printer. Building on its reputation for high-precision printing, Phrozen...
Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B
Cohort 4 follow-up confirms durable hepatitis B surface antigen (HBsAg) loss at 24 weeks post end of treatment (EOT) in BRII-179 anti-HBs responders treated with elebsiran plus pegylated interferon alfa (PEG-IFNα) Data suggest the potential to...
Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
NEW ORLEANS, Nov. 10, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 achieved...
HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers
Late-breaking poster presentations show HCB101's favorable safety, strong receptor occupancy, and promising monotherapy and combination activity in tumors historically unresponsive to immunotherapy TAIPEI, SHANGHAI, and SAN FRANCISCO, Nov. 7, 2025...